# Test Results: statistics/design-review.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/design-review.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: I am planning an experiment and want critical feedback on the design before I begin. I want you to identify potential problems, not just validate my plan.

Research question: {WHAT_YOU_WANT_TO_LEARN}

Experimental design:
- Study system: {ORGANISM, CELL_LINE, POPULATION, etc.}
- Treatment groups: {LIST_ALL_GROUPS_WITH_DESCRIPTIONS}
- Sample size: {N_PER_GROUP_AND_JUSTIFICATION}
- Controls: {POSITIVE/NEGATIVE_CONTROLS}
- Randomization: {HOW_SUBJECTS_ASSIGNED_TO_GROUPS}
- Blinding: {WHO_IS_BLINDED_TO_WHAT}
- Outcome measures: {PRIMARY_AND_SECONDARY_ENDPOINTS}
- Timepoints: {WHEN_DATA_COLLECTED}

Potential confounders I've considered: {LIST_ANY}

Planned analysis: {BRIEF_STATISTICAL_PLAN}

Task: Review this experimental design critically. Please identify:

1. **Strengths**: What aspects of the design are well-constructed?

2. **Missing controls**: Are there controls that should be added?

3. **Potential confounds**: What factors could produce the expected result without the hypothesized mechanism?

4. **Threats to validity**:
   - Internal validity: Could something other than the treatment explain results?
   - External validity: How generalizable are potential findings?

5. **Statistical concerns**:
   - Is the sample size likely adequate?
   - Does the design match the planned analysis?
   - Are there design features that complicate analysis?

6. **Practical issues**: What could go wrong during execution?

7. **Recommendations**: Prioritized list of suggested improvements

Constraints:
- Be critical—I want to find problems now, not after data collection
- Distinguish between essential fixes and nice-to-haves
- If you need more information to evaluate an aspect, ask
- Don't assume expertise I may not have; explain concerns clearly

Context: I am planning an experiment to test whether a high-fiber diet alters gut microbiome-immune interactions in a mouse model of autoimmune disease. I want critical feedback before I begin.

Research question: Does dietary fiber supplementation modify gut microbiome composition and reduce autoimmune inflammation in the EAE mouse model?

Experimental design:
- Study system: C57BL/6 mice, 8 weeks old, female, EAE model (MOG-induced)
- Treatment groups:
  1. EAE + standard diet (n=12)
  2. EAE + high-fiber diet (n=12)
  3. No EAE + standard diet (n=6)
  4. No EAE + high-fiber diet (n=6)
- Sample size: Based on previous EAE studies in our lab showing adequate power at n=10
- Controls: Groups 3-4 are healthy controls
- Randomization: Mice assigned to groups at weaning
- Blinding: Clinical scoring will be performed by blinded observer
- Outcome measures: Clinical EAE score (daily), microbiome composition (16S), T cell populations (flow cytometry)
- Timepoints: Fecal samples at days 0, 7, 14, 21; immune analysis at day 21

Potential confounders I've considered:
- Cage effects (2 cages per group)
- Litter effects
- Food consumption differences

Planned analysis: Compare clinical scores with repeated measures ANOVA; compare microbiome with PERMANOVA; correlate microbiome changes with immune parameters.
```

## Model Output
```


**Critical Review of Your EAE + Fiber Experiment**  
*(All points are framed as potential problems; strengths are noted where the design already mitigates a known issue.)*  

---

## 1. Strengths  

| Aspect | Why it helps |
|--------|--------------|
| **Female C57BL/6 mice, 8 wks old** | Standard for MOG‑EAE; reduces sex‑related variability and matches most published protocols. |
| **Healthy‑control groups (no EAE) for both diets** | Allows you to separate diet‑only effects from disease‑modifying effects. |
| **Daily clinical scoring by a blinded observer** | Minimises observer bias, a major threat in behavioural/clinical read‑outs. |
| **Repeated fecal sampling (days 0, 7, 14, 21)** | Captures temporal dynamics of the microbiome rather than a single snapshot. |
| **Multiple outcome layers (clinical, 16S, flow cytometry)** | Enables mechanistic linking of microbiome shifts to immune changes. |
| **Cage replication (2 cages/group)** | Begins to address cage‑effect confounding. |
| **Consideration of litter, food‑consumption, and cage effects** | Shows you are already thinking about common sources of noise. |

---

## 2. Missing Controls  

| Missing control | Rationale / what it would test |
|-----------------|--------------------------------|
| **Pair‑fed control for the high‑fiber diet** | Fiber changes caloric density and palatability; mice may eat less/more, influencing weight, gut transit, and immunity independent of fiber. Pair‑feeding isolates the nutrient effect from intake differences. |
| **Sham‑immunized (MOG‑negative peptide) + standard/high‑fiber groups** | Controls for any non‑specific immune activation caused by the adjuvant (CFA) or the injection procedure. |
| **Antibiotic‑treated or germ‑free mice receiving fiber** | To test whether the observed effects are truly microbiome‑dependent (i.e., fiber works via the microbiota). |
| **Positive control for fiber efficacy (e.g., inulin‑supplemented diet known to shift microbiota)** | Confirms that your “high‑fiber” diet actually produces a measurable microbiome shift in your hands. |
| **Vehicle control for any gavage or oral dosing (if you plan to give fiber via gavage)** | Rules out stress or irritation from the dosing procedure itself. |
| **Baseline (pre‑EAE) immune profiling** | Without a day‑0 immune read‑out you cannot be sure that observed differences at day 21 are not due to pre‑existing group differences. |

*If any of these are impractical, at least acknowledge them as limitations and discuss how they could bias interpretation.*

---

## 3. Potential Confounds (Factors that Could Mimic a Fiber Effect)

| Confounder | How it could produce the expected result without the hypothesized mechanism |
|------------|-----------------------------------------------------------------------------|
| **Differential food intake** | High‑fiber diet may be less palatable → reduced caloric intake → lower body weight → less severe EAE (weight correlates with disease severity). |
| **Cage‑level microbiota drift** | Even with 2 cages/group, if cages are not rotated, cage‑specific microbiota could dominate and be mistaken for a diet effect. |
| **Litter effects** | Pups from the same dam share early‑life microbiota and genetics; if litters are unevenly distributed across groups, litter‑specific traits could confound outcomes. |
| **Stress from handling/fecal collection** | More frequent sampling in one group (e.g., if you inadvertently sample high‑fiber mice more often) could alter stress hormones, influencing immunity. |
| **Batch effects in 16S sequencing** | If samples from different groups are processed in separate PCR/plate batches, technical variation could masquerade as biological differences. |
| **Variability in MOG/CFA emulsion** | Incomplete emulsification can lead to variable disease onset; if the emulsion preparation differs between diet groups (e.g., due to viscosity changes), disease severity could be confounded. |
| **Circadian timing of sampling** | Gut permeability and immune cell trafficking show diurnal rhythms; sampling at different times of day could introduce noise that looks like a diet effect. |

---

## 4. Threats to Validity  

### Internal Validity  

| Threat | Why it matters | Mitigation / comment |
|--------|----------------|----------------------|
| **Uncontrolled food intake** | Could be the true driver of any observed clinical improvement. | Implement pair‑feeding or monitor daily food consumption and include intake as a covariate. |
| **Cage effects** | Microbiota and stress can be transmitted cage‑wise; with only 2 cages per group, a single cage outbreak could skew results. | Increase cage replication (≥ 4 cages/group) and randomize cage positions; consider rotating cages weekly. |
| **Litter effects** | Early‑life microbiota influences adult immunity; uneven litter distribution could bias groups. | Stratify randomization by litter (e.g., equal numbers of pups from each dam per group). |
| **Blinding limitations** | If the high‑fiber diet changes stool consistency or color, the scorer might infer group membership despite being blinded to the treatment label. | Use opaque, identical‑looking food pellets; have a second person prepare diets and code them; verify blinding integrity by asking scorers to guess group after scoring. |
| **Outcome timing** | Immune analysis only at day 21 (peak disease) misses earlier immune dynamics that could be mechanistically important. | Add an intermediate immune timepoint (e.g., day 14) or collect spleen/MLN at peak and remission. |
| **Statistical independence** | Treating each mouse as independent ignores cage/litter clustering, inflating Type I error. | Use mixed‑effects models with cage (and possibly litter) as random effects. |

### External Validity  

| Concern | Impact on generalizability |
|---------|----------------------------|
| **Single strain, sex, and age** | Findings may not translate to male mice, other strains, or older animals where microbiome‑immune interactions differ. |
| **MOG‑induced EAE model** | Represents a Th1/Th17‑driven disease; may not reflect other autoimmune models (e.g., spontaneous lupus, colitis). |
| **Defined high‑fiber diet composition** | If the diet uses a single fiber source (e.g., cellulose), results may not extrapolate to complex dietary fibers or human diets. |
| **Laboratory‑specific husbandry** | Cage density, bedding type, and ambient microbiota vary across facilities; results may not hold elsewhere. |
| **Short duration (21 days)** | Does not capture chronic or remission phases; effects may be transient. |

---

## 5. Statistical Concerns  

| Issue | Explanation | Recommendation |
|-------|-------------|----------------|
| **Sample size justification** | “Based on previous EAE studies in our lab showing adequate power at n=10” is vague; you need a power calculation that specifies effect size, α, power, and variance estimate for each outcome (clinical score, microbiome distance, flow %). | Perform an a priori power analysis for the primary outcome (e.g., mean clinical score difference). If you lack pilot data, state that n=12 is a *minimum* and plan to increase if interim variance is high. |
| **Repeated‑measures ANOVA assumptions** | Sphericity, normality, and equal variances are often violated with clinical EAE scores (ordinal, non‑normal, missing data if mice die/are euthanized early). | Consider a mixed‑effects model (or generalized estimating equations) with an appropriate covariance structure; or use non‑parametric repeated‑measures tests (e.g., Friedman) as a sensitivity analysis. |
| **Microbiome PERMANOVA** | PERMANOVA is sensitive to differences in dispersion (heterogeneity of variance) as well as location; diet could change variance rather than centroid. | Test for homogeneity of dispersions (PERMDISP) and report both. Consider using distance‑based linear models (DistLM) or differential abundance tools (DESeq2, ANCOM) for taxon‑level inference. |
| **Correlation analyses** | Correlating microbiome composition (high‑dimensional) with immune parameters without correction for multiple testing inflates false positives. | Use multivariate approaches (e.g., Procrustes analysis, Mantel test with permutation, or sparse canonical correlation) and adjust p‑values (FDR). |
| **Multiple outcome testing** | You have three primary domains (clinical, microbiome, immune) each with several tests; risk of Type I error escalates. | Pre‑specify a hierarchical testing scheme (e.g., clinical primary, then microbiome, then immune) or apply a global correction (e.g., Holm‑Bonferroni) across families of tests. |
| **Missing data handling** | Mice that reach humane endpoints early will have incomplete longitudinal data; listwise deletion biases results. | Use mixed‑effects models that handle missing at random, or plan survival analysis (time to reach a clinical score) as a complementary endpoint. |

---

## 6. Practical Issues (What Could Go Wrong During Execution)

| Potential problem | Consequence | Mitigation |
|-------------------|-------------|------------|
| **Diet preparation/storage** | High‑fiber diets can absorb moisture, clump, or mold, leading to inconsistent intake or mycotoxin exposure. | Prepare fresh batches weekly, store in sealed containers at 4 °C, monitor for mold, and record batch numbers. |
| **Food refusal / weight loss** | Mice may lose >15 % body weight, triggering early euthanasia and loss of power. | Monitor body weight twice weekly; have a humane endpoint protocol; consider adding a palatability factor (e.g., a small amount of sucrose) equally to both diets if needed. |
| **Cage‑change stress** | Frequent cage changes for sampling can disturb microbiota and increase corticosterone. | Minimize cage changes; collect feces via gentle handling or use metabolic cages for short periods; allow acclimation before sampling. |
| **Flow cytometry variability** | Antibody lot-to-lot variation or instrument drift can obscure subtle immune shifts. | Use the same antibody lot for all samples, run fluorescence‑minus‑one (FMO) controls, and include a reference sample (e.g., pooled spleen) on each run. |
| **Sequencing batch effects** | If you process all standard‑diet samples first, then high‑fiber, any run‑to‑run variation will be confounded with diet. | Randomize samples across 96‑well plates and sequencing lanes; include technical replicates and a mock community control. |
| **EAE induction failure** | Variability in MOG/CFA emulsion can lead to low incidence, reducing effective n. | Standardize emulsion preparation (e.g., using a vortexer + sonicator), record clinical onset date, and consider pre‑screening for responders. |
| **Blinding breach** | If the diet changes fecal odor or appearance, the person scoring may guess the group. | Use identical‑looking pellets, have a third party code diets, and verify blinding by asking scorers to guess group after the study (report success rate). |
| **Regulatory / IACUC concerns** | High‑fiber diets may alter gut motility, causing diarrhea or prolapse; need to monitor welfare. | Include daily health checks, record stool consistency, and have a plan for supportive care (e.g., gel diet) if needed. |

---

## 7. Recommendations (Prioritized)

### **Essential Fixes (must do before starting)**  

1. **Quantify and control food intake** – Implement pair‑feeding or at least record daily consumption per cage; include intake as a covariate in all models.  
2. **Increase cage replication** – Minimum 4 cages per group (ideally 6) to separate diet effect from cage‑level microbiota; randomize cage positions weekly.  
3. **Stratify randomization by litter** – Ensure each litter contributes equally to each diet/disease condition to eliminate litter confounding.  
4. **Add a pair‑fed control group** (EAE + pair‑fed standard diet) to isolate the effect of fiber from caloric differences.  
5. **Perform an a priori power analysis** for the primary clinical outcome (e.g., detect a 1‑point difference in mean clinical score with 80 % power, α = 0.05) and justify n per group accordingly; adjust if variance is higher than expected.  

### **Highly Recommended (strongly improve interpretability)**  

6. **Collect baseline (day 0) immune phenotypes** (flow cytometry from blood or spleen) to confirm groups are immunologically naïve before EAE induction.  
7. **Add a positive fiber control** (e.g., 5 % inulin) to verify that your high‑fiber diet indeed shifts the microbiome in your facility.  
8. **Implement mixed‑effects models** for clinical scores (random intercept for cage/litter) and for microbiome PERMANOVA (test dispersion).  
9. **Randomize sample processing** for 16S sequencing and flow cytometry across plates/batches; include technical replicates and mock communities.  
10. **Monitor and record stress indicators** (corticosterone in feces, body temperature) to detect unintended stress differences between diet groups.  

### **Nice‑to‑Have (optional, depending on resources)**  

11. **Add a second immune timepoint** (e.g., day 14) to capture dynamics.  
12. **Consider germ‑free or antibiotic‑treated mice** in a follow‑up study to test microbiome dependence.  
13. **Run a pilot cohort (n = 4/group)** to validate diet intake, microbiome shift, and clinical severity before scaling up.  
14. **Explore alternative disease models** (e.g., chronic EAE, spontaneous models) in later work to assess external validity.  

---

### Quick Checklist for Your Protocol Document  

- [ ] Food intake measured daily (grams per mouse per cage).  
- [ ] Cage numbers ≥ 4 per group, positions rotated weekly.  
- [ ] Litter IDs recorded; randomization stratified by litter.  
- [ ] Pair‑fed control group defined.  
- [ ] Power analysis included (effect size, α, power, variance estimate).  
- [ ] Mixed‑effects model specification for longitudinal clinical score.  
- [ ] PERMANOVA + PERMDISP plan for microbiome.  
- [ ] Blinding verification procedure (post‑study guess test).  
- [ ] Baseline immune profiling scheduled.  
- [ ] Diet preparation SOP (batch, storage, moisture check).  
- [ ] Sequencing batch randomization plan.  

Addressing the essential items will substantially reduce the risk that any observed “fiber‑protective” effect is actually due to uncontrolled confounders. Once those are in place, the nice‑to‑have suggestions will let you dig deeper into mechanism and broaden the impact of your findings.  

Good luck with the study—feel free to ping me if you need help drafting the power analysis, mixed‑effects model code, or a detailed SOP for diet preparation!
```

## Overall Assessment
- **Recommendation:** Pass
- **Notes:**
## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
